Project Grant R01NS137434
Award Date
7/1/24
Completion Date
4/30/29
Dollars Obligated
$654K
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $681,536 to conduct research aimed at deciphering the structural basis of repeat-associated non-AUG (RAN) translation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The research will use cryo-electron microscopy, biochemical and genetic approaches to...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $360,100 to The Washington University in St. Louis to investigate the neuroinflammatory mechanisms underlying Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD). The research aims to characterize the role of the ATP8A2 gene and its interaction with the STMN2 gene in regulating phosphatidylserine exposure and neuroinflammation in models of progressive TDP-43 pathology, which...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,359,618 to fund research focused on understanding the role of poly-ADP-ribosylation (parylation) in C9ORF72-related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The key objectives of this 5-year award are to: 1) comprehensively characterize the...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $236,668 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the interactions between the C9ORF72 dipeptide repeat protein poly(GR) and the BAF chromatin remodeling complex. The primary goal is to elucidate how these...
This federal Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to investigate the role of double-stranded RNA (dsRNA) in the neuropathology of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The $2,951,689 award, with a period of performance from Jul 1, 2024 to Mar 31, 2029, will be used by the prime awardee, the University of Colorado, to: Identify the specific RNA species contributing to dsRNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $224,140 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate the mechanisms of circuit dysfunction in frontotemporal dementia (FTD) caused by mutations in the C9ORF72 gene. The key objectives are to: Monitor the progression of neuronal activity and its relationship to neuronal loss in an animal model of C9ORF72-FTD. Determine whether neuronal...
This Project Grant award of $2,219,913 from the National Institutes of Health's National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate environmental risk factors linked to TDP-43 proteinopathies, a hallmark of neurodegenerative disorders like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The 5-year project, led by the University of North Carolina at Chapel Hill, will evaluate a subset of environmental toxicants identified through...
This federal Project Grant award for $2,840,883.00, awarded by the National Institute on Aging under CFDA program 93.866 "Aging Research", supports a proteomic comparison study of sporadic early-onset, late-onset, and autosomal dominant Alzheimer's disease. The goal is to advance the understanding of the pathophysiology and biomarkers of sporadic early-onset Alzheimer's disease, and how it compares to late-onset and inherited forms of the disease. The project will leverage a...
The $427,625 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program will support research at The Washington University in St. Louis to develop a novel cellular model for studying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research will employ direct conversion of fibroblasts into induced motor neurons...